Biosimilars are biologic products that are highly similar to a previously approved reference
(or originator) biologic drug in terms of safety, purity, and potency (efficacy). These …

Background CT‐P13, a biosimilar of the reference product infliximab, has been approved for
the treatment of ulcerative colitis on the basis of the results of trials conducted in patients …

The inflammatory bowel diseases (IBD), which consist of Crohn's disease and ulcerative
colitis, are chronic, incurable immunemediated inflammatory disorders of the intestine. As …

Anti-tumor necrosis factor (TNF) therapy has revolutionized the medical treatment of the
inflammatory bowel diseases (IBD), Crohn's disease (CD), and ulcerative colitis. Twenty …

Biological drugs revolutionized the treatment of inflammatory bowel diseases (IBD) such as
Crohn's disease and ulcerative colitis. However, not all clinically eligible patients have …

Background: Several studies have reported positive efficacy outcomes for patients with
inflammatory bowel disease treated with CT-P13, an infliximab biosimilar. Data from follow …

BACKGROUND Infliximab original has changed the natural history of inflammatory bowel
diseases (IBD) over the past two decades. However, the recent expiration of its patent has …

Background: It has been previously shown that biosimilar infliximab CT-P13 is effective and
safe in inducing remission in inflammatory bowel diseases. We report here the 1-year …

The introduction of tumor necrosis factor (TNF) inhibitors has significantly changed the
treatment landscape in Crohn's disease (CD). The overall therapeutic achievements with …

Biosimilar monoclonal antibodies (mAbs) to TNF are being developed that are highly similar,
but not identical to the innovator molecules. CT-P13, a biosimilar of infliximab, is the first anti …